Novocure (NASDAQ: NVCR), a global oncology company, has announced preliminary financial results for the fourth quarter and full year ended December 31, 2024, showcasing significant revenue growth and operational advancements. The company reported a 19% increase in annual net revenues to $605.2 million and a 21% rise in fourth-quarter revenues to $161.3 million compared to the previous year.
The revenue surge was attributed to the successful launch of Novocure's products in France and improved approval rates in the United States. The U.S., Germany, France, and Japan were significant contributors to the quarter's revenues, with additional revenue from Greater China through a partnership with Zai Lab.
Novocure's CEO, Ashley Cordova, highlighted the expansion of the TTFields treatment platform, including the approval and U.S. launch of Optune Lua® for non-small cell lung cancer and the release of next-generation arrays. The company anticipates further growth in 2025 with additional indication launches.
In regulatory achievements, Novocure received FDA Breakthrough Device designation for TTFields therapy for brain metastases from non-small cell lung cancer and for the treatment of unresectable, locally advanced pancreatic cancer. The FDA also approved the company's new Head Flexible Electrode transducer arrays for use with Optune Gio.
Clinical milestones include the Phase 3 PANOVA-3 trial meeting its primary endpoint, improving overall survival for patients with unresectable, locally advanced pancreatic cancer. Looking ahead, Novocure plans to focus on active patients by indication and material market as the key operating statistic starting Q1 2026.
As of December 31, 2024, Novocure reported a strong financial position with cash, cash equivalents, and short-term investments totaling $959.9 million. The total active patients on TTFields therapy globally reached 4,126, with 4,077 being Optune Gio patients and 20 active non-small cell lung cancer patients on Optune Lua.
The company will discuss the full year and fourth-quarter financial results in a conference call and webcast on Thursday, February 27, 2025. These results are preliminary and subject to completion of the company's annual independent audit.
